Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pivotal, Multicenter, Double Blind Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Mild to Moderate Primary Osteoarthritis of the Hip

NCT01618708 is registered in ClinicalTrials.gov with Genzyme, a Sanofi Company as lead sponsor.

NCT NCT01618708
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01618708 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pivotal, Multicenter, Double Blind Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Mild to Moderate Primary Osteoarthritis of the Hip
Lead sponsor
Genzyme, a Sanofi Company
Phase
Not applicable
Overall status
Completed
Start date
September 30, 2012
Completion date
June 30, 2015
Enrollment
357 (actual)
Sites
48

Conditions

As the registry lists them; a condition with its own page is linked.

osteoarthritis, hip